Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.

ABSTRACT:

Background

We sought to characterize response to immune checkpoint inhibitor (ICI) in non-squamous non-small cell lung cancer (NSCLC) across various CD274 copy number gain and loss thresholds and identify an optimal cutoff.

Materials and methods

A de-identified nationwide (US) real-world clinico-genomic database was leveraged to study 621 non-squamous NSCLC patients treated with ICI. All patients received second-line ICI monotherapy and underwent comprehensive genomic profiling as part of routine clinical care. Overall survival (OS) from start of ICI, for CD274 copy number gain and loss cohorts across varying copy number thresholds, were assessed.

Results

Among the 621 patients, patients with a CD274 CN greater than or equal to specimen ploidy +2 (N = 29) had a signif

SUBMITTER: Murugesan K 

PROVIDER: S-EPMC9438920 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature